Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Delirium Prevention in Elderly Inpatients (PODIUM)
NCT02654314Phase 3Terminated
- Sponsor
- Yale University
- Start
- Jul 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of melatonin in delirium, sponsored by Yale University. Primary endpoint: Incidence of Delirium at 14 days. Started Jul 2016; status: terminated.
02
Drugs
melatonin
03
Conditions
delirium
Beyond the preview
Go deeper on NCT02654314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654314.